BELINDA SÁNCHEZ RAMÍREZ,GRETCHEN BÁEZ BERGADO,NARJARA GONZÁLEZ SUÁREZ,MABEL CRUZ RODRÍGUEZ,DIANA ROSA HERNÁNDEZ FERNÁNDEZ,LISSET CHAO GARCÍA
申请号:
US16494102
公开号:
US20200011870A1
申请日:
2018.03.08
申请国别(地区):
US
年份:
2020
代理人:
摘要:
The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.